Medical devices, healthcare technology and the business of care
PMA approval · P250020

Belotero Volume (+) Lidocaine

Merz North America, Inc. · Decision date May 19, 2026

FDA DECISIONP250020

What did the FDA approve?

FDA records P250020 as an original PMA application. The recorded decision is approval, dated May 19, 2026.

FDA approval order statement

Approval for deep (subcutaneous and/or supraperiosteal) injection to improve volume deficit in the mid-face or to correct mid-face contour deficiencies in adults 22 years or older
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
May 19, 2026

FDA source record

Regulatory record facts

Identifier
P250020
Regulatory pathway
Premarket approval application
Product code
LMH
Decision code
APPR
Decision date
May 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250020 received

    Application receipt date recorded by FDA.

  2. P250020 · FDA decision

    APPR

  3. P250020/S005 · Related supplement

    Belotero Volume (+) Lidocaine Dermal Filler

  4. P250020/S004 · Related supplement

    Belotero Volume (+) Lidocaine

Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250020

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA supplementSep 10, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Merz North America, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6501 Six Forks Rd., Raleigh, NC, 27615

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records